StoxAbbott India vs Gland Pharma: share price & financials comparison
NSE: ABBOTINDIA vs GLAND · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Abbott India vs Gland Pharma at a glance
Abbott India (ABBOTINDIA) has a market capitalisation of ₹55,983 Cr, against ₹52,281 Cr for Gland Pharma (GLAND). Over the past year Gland Pharma has returned +66.4%, compared with -11.3% for Abbott India. On valuation, Abbott India trades at a lower P/E of 34.7 versus 46.3. Abbott India comes out ahead on valuation and profitability. Gland Pharma comes out ahead on growth, momentum and technicals. Across the scored metrics below, Abbott India leads on 5 and Gland Pharma on 6. On StoxGud's 10-point checklist, Abbott India scores 5/10 and Gland Pharma scores 9/10.
| Metric | Abbott India | Gland Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹55,983 Cr | ₹52,281 Cr |
| Revenue (latest FY) | — | ₹6,431 Cr |
| Net profit (latest FY) | — | ₹1,027 Cr |
| Valuation | ||
| P/E | 34.7 | 46.3 |
| P/B | — | 5.05 |
| Dividend yield | — | 0.57% |
| Profitability | ||
| Return on equity | — | 10.9% |
| Net profit margin | 23.1% | 16.8% |
| Operating margin | 28.1% | 26.0% |
| Growth | ||
| Revenue growth (YoY) | +4.3% | +19.6% |
| Net profit growth (YoY) | +17.1% | +47.1% |
| Revenue CAGR (multi-year) | — | +13.2% |
| Financial health | ||
| Debt to equity | — | 0.02 |
| Momentum | ||
| 1-month return | +1.0% | +0.6% |
| 1-year return | -11.3% | +66.4% |
| 3-year CAGR | +4.2% | +26.2% |
| 5-year CAGR | +5.6% | -2.8% |
| 10-year CAGR | +18.8% | — |
| Distance from 52W high | -12.8% | +0.0% |
| Technicals | ||
| RSI (14) | 52 | 60 |
| Price vs 200-day avg | -1.0% | +37.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Abbott India | Gland Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✗ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 5/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Abbott India or Gland Pharma?
Abbott India has a market cap of ₹55,983 Cr and Gland Pharma has a market cap of ₹52,281 Cr as of 06 Nov 2026.
Which has a lower P/E, Abbott India or Gland Pharma?
Abbott India has the lower P/E: Abbott India trades at 34.7 and Gland Pharma at 46.3.
Which gave better returns in the last year, Abbott India or Gland Pharma?
Gland Pharma did better: Abbott India returned -11.3% and Gland Pharma returned +66.4% over one year.
Is Abbott India or Gland Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Abbott India scores 5/10 and Gland Pharma scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.